Press Release

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 12, 2008--Synta
Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company
focused on discovering, developing, and commercializing small molecule
drugs to treat severe medical conditions, today announced that the
Company will be presenting at the Lazard Capital Markets Healthcare
Conference on Wednesday, November 19 at 2:00 p.m. (ET) at The St.
Regis in New York.

A live audio webcast and replay of the presentation will be
available on the "Investors" section of the Company's website,
www.syntapharma.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused
on discovering, developing, and commercializing small molecule drugs
to extend and enhance the lives of patients with severe medical
conditions, including cancer and chronic inflammatory diseases. Synta
has a unique chemical compound library, an integrated discovery
engine, and a diverse pipeline of clinical- and preclinical-stage drug
candidates with distinct mechanisms of action and novel chemical
structures. All Synta drug candidates were invented by Synta
scientists using our compound library and discovery capabilities.
Synta has a partnership with GlaxoSmithKline for the joint development
and commercialization of its lead investigational drug candidate,
elesclomol, which is in a global, pivotal Phase 3 clinical trial for
the treatment of metastatic melanoma. For more information, please
visit www.syntapharma.com.